What Does Northern Biologics Do?

Total employees35
HeadquartersToronto
Founded2014

Northern Biologics was a private biotechnology company (2014-2020) dedicated to the discovery and development of novel, first-in-class therapeutic antibodies targeting the tumor microenvironment to treat cancer and fibrosis. Spun out from the University of Toronto and University Health Network, it leveraged deep expertise in antibody development and cancer biology. Its lead programs explored innovative mechanisms to modulate the immune system and stromal components within tumors. In December 2020, Boehringer Ingelheim acquired key preclinical assets from Northern Biologics, which subsequently led to the wind-down of Northern Biologics' operations.

Where Is Northern Biologics's Headquarters?

HQ Function

Primarily served as the hub for research and development, drug discovery, and corporate operations for its antibody therapeutic programs.

Notable Features:

Operated within JLABS @ Toronto, part of the MaRS Discovery District, providing access to advanced shared laboratory facilities, modern office space, and a vibrant biotech innovation ecosystem.

Work Culture:

As a venture-backed biotech, the work culture was likely characterized by scientific innovation, a results-driven approach, and collaboration, further enhanced by its presence in the JLABS incubator environment.

HQ Significance:

The headquarters was central to Northern Biologics' efforts in pioneering novel antibody therapeutics, strategically positioned within Toronto's prominent life sciences research community and benefiting from the comprehensive resources of the MaRS Discovery District.

Values Reflected in HQ: Its location within a premier innovation hub like MaRS and JLABS underscored its commitment to cutting-edge scientific research, collaboration, and the pursuit of breakthrough cancer treatments.

Location:

While primarily based and focused on research and development in Canada, Northern Biologics' global engagement during its operational years included collaborations with international research entities, participation in global scientific conferences, and interactions with multinational pharmaceutical companies for potential partnerships and licensing, as evidenced by its eventual asset acquisition by the global firm Boehringer Ingelheim. The company did not maintain its own international offices.

Street Address:

661 University Ave, Suite 440 (JLABS @ Toronto)

City:

Toronto

State/Province:

Ontario

Country:

Canada

Where Else Does Northern Biologics Operate Around the World?

N/A - Primarily Single-Site Operation

Address: N/A

Operations were centralized in Toronto to leverage the local biotech ecosystem and maintain a focused R&D effort, typical for a company of its size and stage.

Buying Intent Signals for Northern Biologics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Northern Biologics? Meet the Executive Team

As of April 2025, Northern Biologics' leadership includes:

Philip E. Vickers, D.Phil. - Former President and CEO
Stefan Irion, M.D. - Former Chief Scientific Officer / Head of R&D
Robert Wasserman, M.D. - Former Chief Medical Officer

Who's Investing in Northern Biologics?

Northern Biologics has been backed by several prominent investors over the years, including:

Versant Ventures
Celgene Corporation (acquired by Bristol Myers Squibb)
MPM Capital

What Leadership Changes Has Northern Biologics Seen Recently?

Hire0
Exits3

Following the December 2020 acquisition of its key assets by Boehringer Ingelheim, Northern Biologics commenced a wind-down of its operations. This period saw the transition of its executive team as their roles concluded with the company's operational cessation. No new executive hires were made in the 12 months leading up to and during the wind-down.

Departures

Philip E. Vickers, D.Phil., Departed role following the asset acquisition by Boehringer Ingelheim and the company's operational wind-down.
Stefan Irion, M.D., Departed role following the asset acquisition by Boehringer Ingelheim and the company's operational wind-down.
Robert Wasserman, M.D., Departed role following the asset acquisition by Boehringer Ingelheim and the company's operational wind-down.

What Technology (Tech Stack) Is Used byNorthern Biologics?

Discover the tools Northern Biologics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Northern Biologics Email Formats and Examples

The following email format information for Northern Biologics is based on common industry patterns and is historical, as the company is no longer operational and its domain is inactive.

[first_initial][last]@northernbiologics.com

Format

pvickers@northernbiologics.com (example, not active)

Example

0 (company no longer operational, domain inactive; historically, common formats like this had an estimated 75-85% success rate)%

Success rate

What's the Latest News About Northern Biologics?

Boehringer IngelheimDecember 1, 2020

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Oncology Assets

Boehringer Ingelheim announced the acquisition of Northern Biologics Inc.’s preclinical pipeline of antibodies targeting the tumor microenvironment, significantly expanding Boehringer Ingelheim's immuno-oncology pipeline....more

GlobeNewswireDecember 1, 2020

Northern Biologics to Wind-Down Operations Following Asset Sale to Boehringer Ingelheim

Northern Biologics confirmed that following the sale of its lead preclinical assets to Boehringer Ingelheim, it would initiate an orderly wind-down of its remaining operations, aiming to provide a return to its shareholders....more

Versant Ventures (via PR Newswire)June 21, 2016

Northern Biologics Launches With US$10 Million Series A Financing From Versant Ventures and Celgene Corporation to Develop First-in-Class Antibody Therapeutics

Northern Biologics announced its official launch and a US $10 million Series A financing co-led by founding investor Versant Ventures and Celgene Corporation. The funding was aimed at advancing its pipeline of antibody-based therapeutics for oncology and fibrosis....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Northern Biologics, are just a search away.